Indian Generics Producer Missed Mark on Tests, FDA Says

Drug Industry Daily
A A
A major manufacturer of generic drugs in India failed to follow up as required on laboratory tests that showed its products at two facilities did not meet specifications, in some cases improperly dismissing the red-flag results, the FDA said in a warning letter.

To View This Article:

Login

Subscribe To Drug Industry Daily